BioMensio was established in January 2016 to build on international research programs and 15 patent families covering a mass-sensitive microarray technology based on R&D performed jointly by Siemens AG and VTT Technical Research Center. The BioMensio devices allow frequent and rapid on-site detection of multiple biological targets from a small sample.
The sensing platform consists of microfluidic MEMS and an array of microscopic weighing scale pixels, called a Mass Sensitive Micro-Array (MSMA). These mass-sensitive transducer chips are based on patented Film-Bulk Acoustic Resonance (FBAR) technology combined with conditioning ASICs.
By treating multiple MSMA pixels with a biologically active layer, such as antibodies or DNA, it is possible to screen for multiple biological targets from the same liquid sample in one step.
The ability to detect mass makes the bio-sensor inherently universal and applicable to any analyte – or even DNA, according to BioMensio. The results is fast and cost efficient detection on lab-on-a-chip platform that requires no labelling or analyte modifications.
Typical applications for the miniaturized micro-array platform includes bioscreening for biological targets in saliva, and food and milk safety applications, as well as point-of-care and bio-security applications. "The BioMensio biosensors allow cost-efficient application development for businesses and governmental organizations in food and beverage, healthcare, security and defence segments as well as environmental monitoring area," said Ilari Antila, CEO of BioMensio, in a statement.
Related links and articles: